Tonix Pharmaceuticals Holding Corp. (TNXP)
| Market Cap | 90.56M -49.2% |
| Revenue (ttm) | 29.10M +196.0% |
| Net Income | -159.67M |
| EPS | -12.49 |
| Shares Out | 17.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 619,411 |
| Open | 5.45 |
| Previous Close | 5.37 |
| Day's Range | 5.20 - 5.51 |
| 52-Week Range | 5.01 - 20.56 |
| Beta | 1.79 |
| Analysts | Strong Buy |
| Price Target | 39.00 (+638.64%) |
| Earnings Date | Nov 9, 2026 |
About TNXP
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingu... [Read more]
Financial Performance
In 2025, TNXP's revenue was $13.11 million, an increase of 29.85% compared to the previous year's $10.09 million. Losses were -$124.02 million, -4.63% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for TNXP stock is "Strong Buy." The 12-month stock price target is $39.0, which is an increase of 638.64% from the latest price.
News
Tonix Pharmaceuticals presents data from RELIEF, RESILIENT studies of Tonmya
Tonix Pharmaceuticals (TNXP) presented data from an analysis of the Phase 3 RELIEF and RESILIENT studies of Tonmya for the treatment of fibromyalgia in adults demonstrating outcomes as measured by…
Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain
TONMYA improved Fibromyalgia Impact Questionnaire-Revised (FIQR) symptoms and function scores versus placebo in both domains at Week 14 in RELIEF and RESILIENT Phase 3 pivotal studies Tonix commercial...
Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026
BERKELEY HEIGHTS, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biotechnology company, tod...
Tonix Pharmaceuticals initiated with a Buy at Canaccord
Canaccord analyst Gary Nachman initiated coverage of Tonix Pharmaceuticals (TNXP) with a Buy rating and $18 price target Tonix has been executing well with Tonmya for fibromyalgia, which was recently…
Tonix Pharmaceuticals price target lowered to $26 from $27 at Raymond James
Raymond James analyst Tiago Fauth lowered the firm’s price target on Tonix Pharmaceuticals (TNXP) to $26 from $27 and keeps a Strong Buy rating on the shares. 2026 revenue estimates…
Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain
BERKELEY HEIGHTS, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company,...
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026
BERKELEY HEIGHTS, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company,...
Tonix announces second major managed Medicare payer agreement for TONMYA
Tonix Pharmaceuticals (TNXP) announced a second major managed Medicare agreement for TONMYA for the treatment of fibromyalgia in adults that is effective immediately, adding approximately 21M Medicare...
Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®
New agreement, effective immediately, adds approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.) Commercial and government payer coverage for TONMYA now ...
Tonix Pharmaceuticals Holding Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
TONMYA's launch for fibromyalgia has shown strong early sales growth and broadening access, with a unique mechanism and favorable tolerability. The pipeline includes a phase II-ready Lyme disease antibody and an anti-CD40 ligand program for transplantation, supported by a solid cash position into 2027.
Tonix Pharmaceuticals promotes Thomas Englese to chief commercial officer
Tonix Pharmaceuticals (TNXP) announced the promotion of Thomas Englese to chief commercial officer, effective immediately. Englese has served as Tonix’s executive VP, commercial operations, since Sept...
Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer
BERKELEY HEIGHTS, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company...
Tonix Pharmaceuticals Holding Slides: Investor presentation
Tonix Pharmaceuticals Holding has posted slides in relation to its latest quarterly earnings report, which was published on September 2, 2026.
Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference
BERKELEY HEIGHTS, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company...
Tonix Pharmaceuticals Holding Transcript: Canaccord Genuity's 46th Annual Growth Conference
Recent results show strong uptake of a new fibromyalgia therapy, with net sales tripling quarter-over-quarter and expanded market access. The pipeline includes a monoclonal antibody for Lyme disease prevention entering phase II in 2025 and a phase II study for major depression, both with results expected by 2028.
Tonix Pharmaceuticals price target raised to $27 from $25 at Raymond James
Raymond James raised the firm’s price target on Tonix Pharmaceuticals (TNXP) to $27 from $25 and keeps a Strong Buy rating on the shares. In Tonmya’s second full quarter on…
Tonix Pharmaceuticals Holding Earnings Call Transcript: Q2 2026
Q2 2026 saw robust revenue growth driven by Tonmya's successful launch, expanded market access, and strong refill dynamics, while pipeline programs advanced with pivotal studies in MDD and Lyme disease prevention. Cash runway extends into early Q2 2027.
Tonix Pharmaceuticals Holding Earnings release: Q2 2026
Tonix Pharmaceuticals Holding released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Tonix Pharmaceuticals Holding Quarterly report: Q2 2026
Tonix Pharmaceuticals Holding has published its Q2 2026 quarterly earnings report on August 10, 2026.
Tonix Pharmaceuticals Holding Slides: Q2 2026
Tonix Pharmaceuticals Holding has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 10, 2026.
Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 13...
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
BERKELEY HEIGHTS, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, tod...
Tonix Pharmaceuticals receives Type C meeting minutes from FDA for TNX-4800
Tonix Pharmaceuticals (TNXP) announced the receipt of official minutes from the Type C meeting with the FDA to discuss the company’s plans for an adaptive Phase 2 field study of…
Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.
Alignment with FDA on key elements of the study design support planned start of the Phase 2 study in the first quarter of 2027
Tonix Pharmaceuticals Holding Slides: Investor presentation
Tonix Pharmaceuticals Holding has posted slides in relation to its latest quarterly earnings report, which was published on August 3, 2026.